0001178913-19-000043.txt : 20190103 0001178913-19-000043.hdr.sgml : 20190103 20190103160422 ACCESSION NUMBER: 0001178913-19-000043 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190101 FILED AS OF DATE: 20190103 DATE AS OF CHANGE: 20190103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Domzalski David CENTRAL INDEX KEY: 0001727794 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36621 FILM NUMBER: 19505348 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001606645 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 BUSINESS PHONE: 97289316233 MAIL ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 FORMER COMPANY: FORMER CONFORMED NAME: Foamix Ltd. DATE OF NAME CHANGE: 20140428 4 1 zk1922432.xml OWNERSHIP DOCUMENT X0306 4 2019-01-01 0 0001606645 Foamix Pharmaceuticals Ltd. FOMX 0001727794 Domzalski David C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLTZMAN STREET REHOVOT L3 7670402 ISRAEL 1 1 0 0 CEO Ordinary Shares 2019-01-01 4 A 0 73282 0.00 A 219691 D Option (right to buy) 3.77 2019-01-01 4 A 0 170993 3.77 A 2029-01-01 Ordinary Shares 170993 170993 D These shares are represented by restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer. The ordinary shares underlying this restricted share unit award vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereafter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date. The ordinary shares underlying these options vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereafter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date. /s/ Mutya Harsch as attorney-in-fact for David Domzalski 2019-01-03